These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32948017)

  • 1. A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
    Ocadlikova D; Iannarone C; Redavid AR; Cavo M; Curti A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32948017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
    Anderson E; Mehta P; Heywood J; Rees B; Bone H; Robinson G; Reynolds D; Salisbury V; Mayer L
    Leuk Res; 2018 Nov; 74():121-129. PubMed ID: 30119908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
    Higashi Y; Turzanski J; Pallis M; Russell NH
    Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
    Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
    BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
    Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
    Löfgren C; Albertioni F; Paul C
    Ther Drug Monit; 2005 Oct; 27(5):641-6. PubMed ID: 16175139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
    Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
    Eur J Haematol; 2011 Mar; 86(3):206-15. PubMed ID: 21114538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
    Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.
    Fredly H; Ersvær E; Gjertsen BT; Bruserud O
    Oncol Rep; 2011 Jun; 25(6):1549-56. PubMed ID: 21431284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Ji L; Haider M; Pullarkat V
    Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
    Kanakry CG; Hess AD; Gocke CD; Thoburn C; Kos F; Meyer C; Briel J; Luznik L; Smith BD; Levitsky H; Karp JE
    Blood; 2011 Jan; 117(2):608-17. PubMed ID: 20935254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
    Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
    PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
    Yao YY; Zhu Q; Zou LF; Dou HJ; Chen YM; Tang Y; Hu JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):774-6. PubMed ID: 19549406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.